bimekizumab

Home
Ligands
bimekizumab

GtoPdb Ligand ID: 9411

Synonyms: bimekizumab-bkzx | Bimzelx® | CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1

bimekizumab is an approved drug (EMA (2021), FDA (2023))

Comment: Bimekizumab (UCB4940) is a rat-derived humanized monoclonal antibody that simultaneously targets IL-17A and IL-7F (dual antagonist), with potential for controlling autoimmune conditions mediated by these proinflammatory cytokines. Safety, pharmacokinetics and clinical efficacy of bimekizumab in mild psoriasis were reported in [2]. Claimed in patent WO2008047134 as CA028_0496 [1].

References
1. Adams R, Popplewell AG, Rapecki SE. (2008) Antibody molecules which bind il-17a and il-17f. Patent number: WO2008047134. Assignee: Ucb Pharma S.A.. Priority date: 18/10/2006. Publication date: 24/04/2008.
2. Glatt S, Helmer E, Haier B, Strimenopoulou F, Price G, Vajjah P, Harari OA, Lambert J, Shaw S. (2017) First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol, 83 (5): 991-1001. [PMID:27859546]

References

1. Adams R, Popplewell AG, Rapecki SE. (2008)
Antibody molecules which bind il-17a and il-17f.
Patent number: WO2008047134. Assignee: Ucb Pharma S.A.. Priority date: 18/10/2006. Publication date: 24/04/2008.

2. Glatt S, Helmer E, Haier B, Strimenopoulou F, Price G, Vajjah P, Harari OA, Lambert J, Shaw S. (2017)
First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
Br J Clin Pharmacol, 83 (5): 991-1001. [PMID:27859546]